Innovate Biopharmaceuticals Presents Oral Poster at European Association for the Study of the Liver (EASL) Demonstrating Positive Effect of Larazotide on Reduced Intestinal Permeability in a NASH Preclinical Study
Selected for oral poster tour by the scientific committee in the gut microbiota section at the
Data presented as a poster showing significant effect on gut epithelial integrity thought to be key for bacterial translocation leading to NAFLD and NASH
The intestinal epithelium normally forms a tight seal separating the host from gut contents, via a well-regulated physical barrier. Tight junctions, one of the most important physiologic and pathologic structural complexes, regulate the subtle equilibrium among the gut microbiome, epithelial cells, and the intestinal mucosa, helping to maintain a delicate homeostasis. A meta-analysis based on five clinical studies showed that NAFLD and
In the study being presented today, researchers assessed the effects of larazotide in a preclinical model of
The data has been selected as an oral short presentation as part of the Poster Tour: Gut Microbiota & Liver Disease, Metabolism, Alcohol & Toxicity section:
Section: Poster Tour - Gut Microbiota and Liver Disease, Metabolism, Alcohol & Toxicity
Poster Tour No. FRI-267: Serial measurement of serum dextran absorption by novel competition ELISA demonstrates larazotide acetate significantly improves "leaky gut" in a Western diet murine model of metabolic liver disease.
April 12, 2019at 12:30 pm– 1:00 pmCentral European Time (CET)
- Location: Meeting Point 3, Hall B Reed Messe Wien Exhibition & Congress Center
Rebecca Caffrey, Ph.D.
The paper poster presentation will be displayed in Reed Messe Wien Exhibition & Congress Center Hall B on
Nonalcoholic steatohepatitis (
About Larazotide Acetate for Celiac Disease
In celiac disease, larazotide is the only drug which has successfully met its primary endpoint with statistical significance in a Phase 2b efficacy clinical trial (342 patients). Innovate completed the End of Phase 2 Meeting with the FDA and is preparing to launch the Phase 3 registration clinical trials for celiac disease in the second quarter of 2019. Nearly 600 subjects have been exposed to larazotide in clinical trials, and a safety profile comparable to placebo has been demonstrated. Larazotide has received Fast Track designation from the FDA for celiac disease
Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking, such as gliadin fragments in celiac disease, and bacterial toxins and immunogenic antigens in nonalcoholic steatohepatitis (
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. These risks and uncertainties include, but may not be limited to, those described in our Annual Report on Form 10-K filed with the SEC on March 18, 2019, and in any subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
SOURCE: Innovate Biopharmaceuticals, Inc.
- Luther, J et. al. Hepatic Injury in NASH Contributes to Altered Intestinal Permeability. CMGH 2015 Vol. 1, Issue 2, pp. 222-232. (doi: 10.1016/j.cmgh.2015.01.001)
- Rahman, K et. al. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a
Diet Highin Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016 Oct; 151(4): 733-746. (doi: 10/1053/j.gastro.2016.06.022)
Source: Innovate Biopharmaceuticals, Inc